Trial of FOLF(HA)Iri With Cetuximab in mCRC
- Sponsor
- Western General Hospital, Australia
- Study ID
- NCT02216487
- Phase
- PHASE2
- Status
- Unknown
Conditions
- Metastatic Colorectal Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- HA-Irinotecan — DRUGHA-Irinotecan is administered as part of FOLFIRI/cetuximab treatment in place of irinotecan for treatment of mCRC.
Study Details
As an approach to improve efficacy and provide clinical benefit to cancer patients undergoing chemotherapeutic treatment regimens, Alchemia Oncology has developed a novel means for delivering anti-cancer agents to tumours. The drug delivery platform is based on the use of hyaluronic acid (HA), a novel excipient, in which, formulation with HA results in optimisation of cytotoxic drug uptake and retention within solid tumours. In the specific example of HA-Irinotecan, this new formulation of irinotecan has demonstrated enhanced efficacy in both nonclinical and early clinical studies. The current study is an investigation into the use of HA-Irinotecan in a Phase II single arm trial of FOLF(HA)iri plus cetuximab in irinotecan-naïve second line patients with KRAS wild type metastatic colorectal cancer. The study objectives are to confirm the safety and efficacy of FOLF(HA)iri plus cetuximab as second-line therapy in irinotecan-naïve metastatic colorectal cancer patients. It is expected that the study recruit approximately 40-50 patients in 1 year with subsequent treatment and follow up; thus the trial will run for approximately 2-3 years.
Key Dates
- Start date
- Jun 30, 2014
- Status verified
- Aug 2014
- Primary completion
- Jun 30, 2016
- Completion
- Nov 30, 2016
Study Design
- Enrollment
- 45 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: HA-IrinotecanHA-Irinotecan is administered as part of FOLFIRI/cetuximab treatment in place of irinotecan.
Primary Outcome Measure
Safety [ Time Frame: 2 years ]
Central Contacts
- Peter Gibbs, MD
Related Studies
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerPHASE2 · Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- A Study of ART0380 for the Treatment of Advanced or Metastatic Solid TumorsPHASE1/PHASE2 · Recruiting · Artios Pharma Ltd · Birmingham, Alabama
- A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)PHASE1 · Recruiting · Hoffmann-La Roche · Birmingham, Alabama
- Couple-Based Mindfulness Intervention for Metastatic Colorectal CancerRecruiting · University of Colorado, Denver · Aurora, Colorado